Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1570

O,.o circa 2020.

Scientists from the UCLA Jonsson Comprehensive Cancer Center have developed a simple, high-throughput method for transferring isolated mitochondria and their associated mitochondrial DNA into mammalian cells. This approach enables researchers to tailor a key genetic component of cells, to study and potentially treat debilitating diseases such as cancer, diabetes and metabolic disorders.

A study, published today in the journal Cell Reports, describes how the new UCLA-developed device, called MitoPunch, transfers mitochondria into 100000 or more recipient cells simultaneously, which is a significant improvement from existing mitochondrial transfer technologies. The device is part of the continued effort by UCLA scientists to understand mutations in mitochondrial DNA by developing controlled, manipulative approaches that improve the function of human cells or model human mitochondrial diseases better.

The ability to generate cells with desired mitochondrial DNA sequences is powerful for studying how genomes in the mitochondria and nucleus interact to regulate cell functions, which can be critical for understanding and potentially treating diseases in patients.

Continue reading “New UCLA-developed device transfers mitochondria into 100,000 or more recipient cells” | >

In Michelle O’Malley’s lab, a simple approach suggests a big leap forward in addressing the challenge of antibiotic-resistant bacteria.

Scientists have long been aware of the dangerous overuse of antibiotics and the increasing number of antibiotic-resistant microbes that have resulted. While over-prescription of antibiotics for medicinal use has unsettling implications for human health, so too does the increasing presence of antibiotics in the natural environment. The latter may stem from the improper disposal of medicines, but also from the biotechnology field, which has depended on antibiotics as a selection device in the lab.

“In biotech, we have for a long time relied on antibiotic and chemical selections to kill cells that we don’t want to grow,” said UC Santa Barbara chemical engineer Michelle O’Malley. “If we have a genetically engineered cell and want to get only that cell to grow among a population of cells, we give it an antibiotic resistance gene. The introduction of an antibiotic will kill all the cells that are not genetically engineered and allow only the ones we want — the genetically modified organisms [GMOs] — to survive. However, many organisms have evolved the means to get around our antibiotics, and they are a growing problem in both the biotech world and in the natural environment. The issue of antibiotic resistance is a grand challenge of our time, one that is only growing in its importance.”

Read more | >

One of the first people in the UK to have a double hand transplant has said her progress has been “phenomenal”, as she continues to pick up new skills two years on.

Cor Hutton, from Lochwinnoch in Renfrewshire, was the first patient in Scotland and the third in the UK to successfully have the procedure, having had her hands and feet amputated in 2013 after suffering acute pneumonia and sepsis which nearly killed her.

On the second anniversary of coming round from the 12-hour operation on January 9 2019, Ms Hutton paid tribute to the donor and the medical team as she said she is “very lucky”.

Read more | >

Biotechnologists at Delft University of Technology have built an artificial chromosome in yeast. The chromosome can exist alongside natural yeast chromosomes, and serves as a platform to safely and easily add new functions to the micro-organism. Researchers can use the artificial chromosome to convert yeast cells into living factories capable of producing useful chemicals and even medicines.

Biotechnologists from all over the world are trying to engineer and other micro-organisms such that they can produce useful substances. To do this, they have to make adjustments to the existing genetic material of the cell. For example, they insert a number of genes into the genome using CRISPR-Cas9, or switch off existing genes, thereby gradually transforming yeast into ‘cell factories’ that produce useful substances.

The disadvantage of this method is that it is not possible to make all the necessary changes at once, but that several rounds of genetic manipulation are needed. This is time-consuming. Additionally, multiple sessions of DNA-tinkering using CRISPR-Cas9 can lead to mutations that disrupt (essential) functions. The result of this could be, for instance, that the metabolism of the cell is disrupted, causing problems with growth and division.

Read more | >

Alzheimer’s Disease (AD) is probably more diverse than our traditional models suggest.

Postmortem, RNA sequencing has revealed three major molecular subtypes of the disease, each of which presents differently in the brain and which holds a unique genetic risk.

Such knowledge could help us predict who is most vulnerable to each subtype, how their disease might progress and what treatments might suit them best, potentially leading to better outcomes.

Read more | >